Mylan Receives FDA Approval for Metoprolol Tartrate and Hydrochlorothiazide Tablets

Mylan Also Announces Tentative Approval for Cetirizine Hydrochloride Tablets and Sertraline Hydrochloride Tablets

PITTSBURGH, Aug. 23 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Metoprolol Tartrate and Hydrochlorothiazide Tablets, 50/25 mg, 100/25 mg, and 100/50 mg strengths. Metoprolol Tartrate and Hydrochlorothiazide Tablets are the generic version of Novartis' Lopressor HCT® Tablets.

Mylan also announced that the FDA has granted tentative ANDA approval for Mylan Pharmaceuticals' Cetirizine Hydrochloride Tablets, 5 mg and 10 mg, and Sertraline Hydrochloride Tablets, 25 mg (base), 50 mg (base) and 100 mg (base). Cetirizine Hydrochloride and Sertraline Hydrochloride are the generic versions of Pfizer's Zyrtec® and Zoloft®, respectively.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

SOURCE Mylan Laboratories Inc.
08/23/2004 CONTACT: Heather Bresch, Public Relations, +1-724-514-1800, or Kris King, Investor Relations, +1-724-514-1800, both of Mylan Laboratories Inc.
Web site: http://www.mylan.com